Most mainstream docs don't prescribe it because they don't have a drug rep in their office pushing it. Naltrexone has been fda approved since the 80's. There is no pharma interest in it because the drug is already available and at a low cost.
Intelligent open minded docs seem to be pretty easy about prescribing it. It has minimal side effects and can be taken along with other meds.
Some of the MS results have been astounding, and the Crohn's results, as published so far, were great enough for my GI doc to actually be excited for me to take it. I think this would be a great option for you to consider, and if you're motivated, I'm sure you can find a doc to help you.
As far as evidence goes, I'm not too sure exactly what the previous poster was getting at, but I thought I'd get you started with this:
> LDN for Crohn’s disease—Penn State College of Medicine, Hershey, PA
Dr. Jill Smith’s original article, "Low-Dose Naltrexone Therapy Improves Active Crohn’s Disease," was published in the Jan 11, 2007 online edition of the American Journal of Gastroenterology (2007;102:1–9) [print edition Apr '07]. This was the first clinical study of LDN published by a US medical journal. Dr. Smith, Professor of Gastroenterology at Pennsylvania State University's College of Medicine, found that two-thirds of the patients in her pilot study went into remission and fully 89% of the group responded to LDN treatment to some degree. She concluded that “LDN therapy appears effective and safe in subjects with active Crohn’s disease.” That open-label Penn State trial demonstrated the efficacy of LDN in a small group of patients.
As a result, Dr. Smith received an NIH grant that permitted a more definitive Phase II placebo-controlled clinical trial, which by September 2008 had already studied almost all of the 40 patients it plans to include. With just a few patients yet to be added to the study, Dr. Smith is very optimistic about the usefulness of LDN in inflammatory bowel diseases, such as Crohn’s disease. (See the trial website.)
Dr. Smith’s most recent research on the effects of LDN is a double blind placebo controlled Phase ll study of youngsters from ages 6 to 17 with active Crohn’s disease. It was launched at Penn State in July 2008 and is expected to run until July 2010. Participants “will be treated with either naltrexone or placebo for the first 8 weeks then all subjects will receive active naltrexone drug the last 8 weeks.” For information about joining the trial, contact Sandra Bingaman, RN, at 717-531-8108 or email@example.com. (Please see the trial website.)
Low-dose naltrexone therapy improves active Crohn's disease.
Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS.
Department of Medicine, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, USA.
OBJECTIVES: Endogenous opioids and opioid antagonists have been shown to play a role in healing and repair of tissues. In an open-labeled pilot prospective trial, the safety and efficacy of low-dose naltrexone (LDN), an opioid antagonist, were tested in patients with active Crohn's disease. METHODS: Eligible subjects with histologically and endoscopically confirmed active Crohn's disease activity index (CDAI) score of 220-450 were enrolled in a study using 4.5 mg naltrexone/day. Infliximab was not allowed for a minimum of 8 wk prior to study initiation. Other therapy for Crohn's disease that was at a stable dose for 4 wk prior to enrollment was continued at the same doses. Patients completed the inflammatory bowel disease questionnaire (IBDQ) and the short-form (SF-36) quality of life surveys and CDAI scores were assessed pretreatment, every 4 wk on therapy and 4 wk after completion of the study drug. Drug was administered by mouth each evening for a 12-wk period. RESULTS: Seventeen patients with a mean CDAI score of 356 +/- 27 were enrolled. CDAI scores decreased significantly (P= 0.01) with LDN, and remained lower than baseline 4 wk after completing therapy. Eighty-nine percent of patients exhibited a response to therapy and 67% achieved a remission (P < 0.001). Improvement was recorded in both quality of life surveys with LDN compared with baseline. No laboratory abnormalities were noted. The most common side effect was sleep disturbances, occurring in seven patients. CONCLUSIONS: LDN therapy appears effective and safe in subjects with active Crohn's disease. Further studies are needed to explore the use of this compound.
also some of the folks above suggested taking a look at http://www.lowdosenaltrexone.org/
I found the conference videos covered MS quite a lot.
All the best in your quest for a cure!!